31 results about "Viral pneumonia" patented technology

The invention belongs to the technical field of biotechnology and genetic engineering, and particularly relates to application of recombinant RASA3 in preparation of a medicine for preventing and treating viral pneumonia. The recombinant RASA3 is used for promoting autophagy degradation of a transcription factor CEBP / beta protein and reducing the expression level of the transcription factor CEBP / beta protein, so that generation of inflammatory factors such as IL-6 is reduced, and inflammatory damage caused by excessive antiviral innate immune response in the virus infection process is improved. The invention provides a novel treatment strategy for inflammatory diseases caused by RNA viruses such as influenza and respiratory syncytial virus infection.

The application discloses application of an aloe oral liquid in preparation of a medicine for treating acute viral pneumonia. A preparation method of the aloe oral liquid comprises the following steps: after fresh aloe leaves are washed and peeled, the fresh aloe leaves are scraped to prepare fresh aloe gel; the fresh aloe gel liquid is placed in a light reaction tank, and is subjected to blue light, red light and no light alternately under low-temperature conditions; the fresh aloe gel after light treatment is pumped into a decocting and concentrating tank, and is concentrated to a supernatant with a density of 1.10 kg / m 3 1.2 kg / m 3 between, is filled and sealed after cooling, and is sterilized to obtain the aloe oral liquid. The application promotes clinical indications of fresh aloe leaves, provides a new drug selection for clinical treatment of acute viral pneumonia, provides a technical reference for industrial production of fresh aloe leaf medicine products, and promotes inheritance and innovation of traditional Chinese medicines with clinical application as a foothold.

The invention discloses a traditional Chinese medicine preparation for treating viral pneumonia. The traditional Chinese medicine preparation comprises the following components in parts by weight: 10-20 parts of ginseng, 9-15 parts of parasitic loranthus, 4-6 parts of schisandra chinensis, 6-9 parts of gastrodia elata, 6-9 parts of cassia twig, 6-9 parts of divaricate saposhnikovia root, 3-4.5 parts of prepared fructus evodiae, 10-20 parts of salvia miltiorrhiza, 6-9 parts of angelica sinensis, 6-9 parts of ligusticum wallichii, 8-12 parts of cortex moutan, 6-9 parts of radix paeoniae rubra, 6-9 parts of pericarpium citri reticulatae, 6-9 parts of rhizoma pinellinae praeparata and 6-9 parts of honey-fried The traditional Chinese medicine preparation disclosed by the invention is high in effective rate, can quickly relieve inflammatory response and remarkably reduce release of inflammatory mediators, and can quickly bring down a fever of a patient, and the average time is about 29 hours.

This invention provides a traditional Chinese medicine composition for treating viral pneumonia in calves, its preparation method, and its application, belonging to the field of veterinary drug technology. The traditional Chinese medicine composition provided by this invention comprises the following raw materials in parts by weight: 15-20 parts of Gentiana scabra, 15-20 parts of Gardenia jasminoides, 15-20 parts of Scutellaria baicalensis, 10-15 parts of Bupleurum chinense, 25-35 parts of Rehmannia glutinosa, 25-35 parts of Plantago asiatica, 15-20 parts of Alisma plantago-aquatica, 25-35 parts of Akebia trifoliata, 10-15 parts of Angelica sinensis, 25-35 parts of Smilax glabra, 15-20 parts of Dioscorea hypoglauca, 25-35 parts of Dictamnus dasycarpus, and 10-15 parts of Glycyrrhiza uralensis (processed). The traditional Chinese medicine composition of this invention can effectively treat viral pneumonia in calves, and also has advantages that antibiotics cannot possess, such as being green and safe, residue-free, having few toxic side effects, low cost, convenient production, and being less likely to produce drug-resistant bacteria.

The invention discloses application of a polygonatum odoratum polysaccharide extract in preparation of a medicine for treating viral pneumonia, and belongs to the technical field of medicines. Through experiments, the applicant discovers that the polygonatum odoratum polysaccharide extract can significantly reduce the fluorescence intensity of neutrophils and macrophages in poly (I: C) induced zebrafish viral pneumonia model swimming sacs, has an obvious antiviral effect on zebrafish, can reduce the expression of pro-inflammatory factors tnf alpha, il6 and il12, has an obvious anti-inflammatory effect, and can be used for preparing anti-inflammatory drugs for treating zebrafish viral pneumonia. The compound is expected to be used for preparing anti-viral pneumonia drugs.

The application relates to an application of a traditional Chinese medicine composition in a drug for viral pneumonia, which comprises 10-15 parts of wind-preventing, 10-15 parts of perilla leaf, 2-6 parts of Ephedra, 7-9 parts of Schisandra chinensis, 7-9 parts of white ginkgo, 7-9 parts of bitter almond, 7-9 parts of purple aster, 7-9 parts of dogwood fruit and 7-9 parts of lily of the valley. The traditional Chinese medicine composition can obviously inhibit the increase of the lung index of respiratory syncytial virus (RSV) infected mice and has a better treatment effect on viral pneumonia.

The present invention relates to the field of pharmaceutical applications, and in particular to a marker for viral pneumonia and its application, wherein the marker for viral pneumonia is prostaglandin E2 and / or prostaglandin M. The present invention uses prostaglandin E2 and / or prostaglandin M as markers for viral pneumonia, and the use of cyclooxygenase II inhibitors can effectively and quickly reduce prostaglandins, reverse the progression of common and severe cases, block the occurrence of critical illness, promote viral conversion to negative, pneumonia absorption and health recovery. The drug will expand its clinical use scope upon further confirmation of its efficacy, incorporate the treatment method into clinical diagnosis and treatment plans, and provide new strategies and diagnosis and treatment methods for the comprehensive treatment of new coronary pneumonia.

The application discloses a drug delivery system targeting lung alveolus microenvironment oxidation and reduction as well as a preparation method and application thereof, and comprises nanoparticles self-assembled by amphiphilic GSH-(oxi)PEI-PCL polymers, wherein the nanoparticles load fat-soluble drugs or fluorescent dyes, GSH in the amphiphilic GSH-(oxi)PEI-PCL polymers is connected with (oxi)PEI-PCL through a disulfide bond, and the (oxi)PEI-PCL is PEI-PCL subjected to partial oxidation. The pharmacodynamic test result shows that the drug delivery system can realize passive targeting aggregation of drugs in a lesion and microenvironment oxidation and reduction sensitive distribution, meanwhile, the drug delivery system shows an antioxidation effect in a lesion microenvironment and intracellular, realizes more accurate drug distribution effect and in-vivo treatment effect, and provides a new drug route for treatment of lung diseases such as premature lung dysplasia, bacterial / viral pneumonia or burn inhalation lung injury.

The use of cellular microparticles in the treatment of respiratory viral pneumonia has been disclosed. Tumor cell-derived microparticles (MPs) include cellular vesicles released by apoptotic tumor cells. The cellular vesicles express spike protein-binding receptors on their surfaces. MPs have high biosafety. In addition, it has been found that the receptors on the surface of microparticles have virus adsorption ability, and macrophages can efficiently take up MPs, which can be used to treat viral pneumonia.

The invention belongs to the technical field of preparation of peptides, and particularly relates to a spirulina peptide, a preparation method, a product and application. The invention provides a spirulina peptide. The spirulina peptide comprises a first algae peptide, a second algae peptide, a third algae peptide, a fourth algae peptide and a fifth algae peptide. According to the preparation method of the spirulina peptide provided by the technical scheme, the neutral protease can preliminarily decompose protein in spirulina, the binding structure of the protein and polysaccharide is destroyed, and macromolecular protein is decomposed into medium-sized peptide fragments. Alkaline protease can deeply hydrolyze protein to generate the antiviral pneumonia active peptide with biological activity. And the papain can accurately regulate and control the molecular weight of the peptide fragment, so that the generated peptide fragment has relatively high water solubility and emulsifying activity, and the antiviral effect is high. Results of embodiments show that the spirulina peptide provided by the invention has the efficacy of resisting viral pneumonia.

The invention discloses an application of an aloe oral liquid in preparation of a medicine for treating acute viral pneumonia. The preparation method of the aloe oral liquid comprises the following steps: cleaning and peeling fresh aloe leaves, and scraping to prepare fresh aloe gel; putting the fresh aloe gel liquid into an illumination reaction tank, and carrying out blue light, red light and dark alternate treatment under a low-temperature condition; pumping the fresh aloe gel subjected to illumination treatment into a decoction concentration tank, concentrating until the liquid medicine is clear liquid with the density of 1.10 kg / m < 3 > to 1.2 kg / m < 3 >, cooling, filling, sealing and sterilizing to obtain the aloe gel. Clinical indications of the fresh aloe leaves are promoted, a new medication choice is provided for clinical treatment of acute viral pneumonia, technical reference is provided for industrial production of fresh aloe leaf medicine products, and traditional Chinese medicine inheritance and innovation with clinical application as a foothold are promoted.

The present invention refers to an in vitro method for identifying biomarkers or biomarker signatures for the differential diagnosis between viral and bacterial pneumonia in a patient, for the differential diagnosis between viral and bacterial pneumonia in a patient and / or for selecting a therapy for a patient suffering from pneumonia.

The invention discloses a drug delivery system targeting alveolar microenvironment redox and a preparation method and application thereof.The drug delivery system comprises nanoparticles formed by self-assembly of an amphiphilic GSH-(oxi) PEI-PCL polymer, fat-soluble drugs or fluorescent dyes are loaded in the nanoparticles, GSH and (oxi) PEI-PCL in the amphiphilic GSH-(oxi) PEI-PCL polymer are connected through a disulfide bond, and the lipid-soluble drugs or fluorescent dyes are loaded in the nanoparticles. And the (oxi) PEI-PCL is the PEI-PCL subjected to partial oxidation. Pharmacodynamic test results show that the drug delivery system provided by the invention can realize passive targeting aggregation in a focus and microenvironment redox sensitive distribution of the drug, simultaneously shows antioxidant effects in the focus microenvironment and cells, realizes a relatively exact drug distribution effect and an in-vivo treatment effect, and has a wide application prospect. The invention provides a new drug approach for the treatment of lung diseases such as premature lung dysplasia, bacterial / viral pneumonia or burn inhalation lung injury and the like.

In order to solve the problems that an existing viral pneumonia related prediction model lacks accurate distinguishing of disease grading, model construction depends on laboratories and iconography data, and interpretability is insufficient, the invention provides an instant interpretable viral pneumonia disease grading distinguishing model construction method based on symptoms and signs. Comprising the following steps: acquiring clinical information of a subject, and constructing a sample data set; determining N preliminary clinical manifestation variables, and screening out M variables as clinical symptom sign feature vectors; respectively constructing a plurality of machine learning models, and determining an optimal model; the M clinical symptom sign feature vectors are incorporated into an optimal model, and a viral pneumonia condition grading discrimination model is established; carrying out SHAP interpretability analysis on the optimal model; and constructing an ordered logistic regression model, drawing a normogram, and displaying scores corresponding to different clinical symptom sign feature vectors and illness state grading discrimination probabilities according to the normogram, so as to realize accurate identification of early illness states and clinical convenience operability.

The invention provides a traditional Chinese medicine tea composition for improving viral pneumonia and a preparation method and application thereof, and relates to the technical field of traditional Chinese medicine, the traditional Chinese medicine tea composition comprises the following components: 11-18 parts of perilla leaf, 7-13 parts of honeysuckle, 7-13 parts of polygonatum odoratum, 5-12 parts of scorched hawthorn fruit, 4-8 parts of platycodon grandiflorum, 3-7 parts of pericarpium citri reticulatae, 3-7 parts of liquorice, 3-7 parts of chrysanthemum, 2-5 parts of osmanthus fragrans, 0.3-0.6 part of stevia rebaudiana, and 6-14 parts of black tea. An anti-inflammatory effect experiment of THP-1 cells proves that the traditional Chinese medicine tea composition has an improvement effect on viral pneumonia, specifically, the traditional Chinese medicine tea composition can effectively reduce IL-6 expression and has good anti-inflammatory activity; the expression of inflammatory indexes NO and IL-6 of RAW264.7 cells induced by lipopolysaccharide LPS is obviously reduced; the traditional Chinese medicine tea composition can be applied to preparation of anti-virus pneumonia products.

This invention relates to the field of compound essential oils of traditional Chinese medicine, and particularly to a compound essential oil of traditional Chinese medicine for the adjuvant intervention against Streptococcus pneumoniae and its preparation method. The raw materials include the following by weight: 3-8 parts of patchouli essential oil; 2-6 parts of clove essential oil; 2-5 parts of costus root essential oil; 2-6 parts of nard essential oil; 3-7 parts of calamus essential oil; 1-4 parts of asarum essential oil; 3-8 parts of peppermint essential oil; 2-6 parts of artemisia essential oil; 3-7 parts of eupatorium essential oil; 45-80 parts of base oil; 2-5 parts of solubilizer; and 1-3 parts of penetration enhancer. This invention addresses the core issues of "respiratory inflammation, sputum accumulation, and decreased body defense" caused by Streptococcus pneumoniae. Through the scientific formulation of active molecules from nine kinds of Chinese herbal essential oils, a comprehensive synergistic system is formed, which has the functions of "antibacterial and antiviral, anti-inflammatory and lung-clearing, expectorant and cough-relieving, and enhanced defense." It features strong synergistic activity of active molecules, high specificity, high retention and utilization rate of active molecules, safe and convenient use, wide applicability, and simple preparation process.

The present invention refers to an in vitro method for the diagnosis of a Mycoplasma pneumoniae infection and / or for the differential diagnosis between a Mycoplasma pneumoniae pneumonia and other bacterial or viral pneumonias and / or for assessing whether to treat a patient suffering from pneumonia with a macrolide antibiotic.

The invention belongs to the technical field of medicines, and discloses a composition for improving bioavailability of arecoline. Specifically, the composition specifically comprises arecoline and magnolol, and the weight ratio of arecoline to magnolol in the pharmaceutical composition is (1: 0.1)-(1: 15). According to the composition, the in-vivo bioavailability of the arecoline can be remarkably improved, the half-life period and the average residence time of the arecoline can be prolonged, the application range of the arecoline is widened, and the treatment effect of the arecoline on diseases such as tapeworm infection, abdominal distension, diarrhea, edema, cancer, Alzheimer's disease, cerebral apoplexy, epilepsy and viral pneumonia can be better exerted.

This invention provides an application of urinary exosome proteins as diagnostic biomarkers for viral pneumonia. The urinary exosome proteins include one or more combinations of ANPEP, ASAH1, COL11A1, EHD4, HEXB, LGALS3BP, SERPINA1, and SERPING1. By using extracted urinary exosomes for the detection of protein-based biomarkers related to viral pneumonia, effective diagnosis of viral pneumonia can be achieved.

The application discloses a traditional Chinese medicine composition, which comprises the following raw materials: shengteng, honeysuckle, chrysanthemum, peppermint, forsythia, platycodon, radix peucedani, anemarrhena, radix pini, radix styracis, scabrousfruit, calcined turtle, artemisia, apricot kernel, gypsum, ephedra, licorice, ophiopogon, radix scrophulariae, radix bupleuri. The application further discloses a preparation containing the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of a medicine for treating viral pneumonia. The traditional Chinese medicine composition has a rapid relieving effect on high fever and cough caused by viral pneumonia, can effectively treat viral pneumonia, and relieve the pain of patients. The safety and effectiveness of the traditional Chinese medicine composition are proved through years of clinical practice.

The present invention belongs to the technical field of traditional Chinese medicine preparations, and specifically relates to a traditional Chinese medicine composition for treating viral pneumonia of the evil-heat obstructing lung type and a preparation method thereof. The traditional Chinese medicine composition comprises the following medicinal materials in parts by weight: 8-12 parts of northern bupleurum, 8-12 parts of scutellaria baicalensis slices, 8-10 parts of French pinellia, 8-12 parts of pseudoginseng, 10-20 parts of forsythia, 10-20 parts of honeysuckle, 3-7 parts of siler, 8-12 parts of astragalus, 11-13 parts of bran-fried atractylodes, 8-12 parts of liquorice slices, 3-7 parts of ginger, 3-7 parts of jujube, 8-12 parts of platycodon, 8-12 parts of schizonepeta, 4-8 parts of cicada slough, 8-10 parts of cyperus rotundus, 20-40 parts of reed rhizome, and 20-40 parts of imperata rhizome. The invention is a pure Chinese medicine preparation, which has the effects of clearing away heat from the interior, invigorating qi and strengthening the body, has a precise therapeutic effect, few side effects, can achieve the effect of treating both the symptoms and the root cause, and the preparation method has the advantages of being suitable for industrial production, and is easy to develop and apply.

The dalbergia odorifera tea is prepared from Hainan dalbergia odorifera and five cereals (rice, sorghum, wheat, buckwheat and millet), dalbergia odorifera is added, the production method comprises the steps of raw material preparation, mixing, fermentation, distillation, aging and packaging, and active ingredient extraction is optimized. Through the synergistic effect of flavonoid compounds in Hainan dalbergia odorifera, nutritional ingredients of five cereals and the blood activating effect of lignum dalbergiae odoriferae, the cardiovascular function is remarkably improved, and the auxiliary effects of improving sleep, preventing senile dementia, dissolving thrombus and resisting viral pneumonia are achieved.

The present invention discloses the use of sisal sapogenin in preparing a medicament for treating influenza and viral pneumonia thereof, wherein the influenza virus is influenza A and the viral pneumonia is influenza A viral pneumonia. The sisal sapogenin (Tigogenin) can reduce the expression of influenza virus mRNA and influenza virus NP protein in vitro. In vivo, it can inhibit the inflammatory pathology of lung tissue caused by influenza virus and reduce the lung index. Since sisal sapogenin has a significant inhibitory effect on the replication of influenza virus, the sisal sapogenin provided by the present invention provides a new medicament for treating influenza and viral pneumonia thereof.

Abstract: This invention discloses a traditional Chinese medicine composition (Da Zhuque Decoction) with multi-target antiviral and anti-inflammatory activities, its preparation method, and its application. The composition consists of the following raw materials in parts by weight: Alisma plantago-aquatica 2-4 parts, Prunus armeniaca 4-6 parts, Chrysanthemum indicum 4-6 parts, Artemisia annua 5-7 parts, Morus alba leaf 5-7 parts, Gypsum 5-7 parts, Poria cocos 7-9 parts, Scutellaria baicalensis 8-10 parts, Rehmannia glutinosa 8-10 parts, Plantago asiatica 11-13 parts, Taraxacum mongolicum 14-16 parts, and Glycyrrhiza uralensis 3-5 parts. This invention overcomes the limitations of traditional qualitative formulation of traditional Chinese medicines. By limiting the specific synergistic ratio of artemisinin and baicalin (1:2.5~3.0), it achieves highly efficient inhibition of respiratory viruses (IC50=12.5μg / mL) and significant downregulation of inflammatory factors (IL-6, TNF-α). Meanwhile, the preparation process of "plaster decoction first - licorice extraction alone" solves the problem of easy decomposition of heat-sensitive components, increasing the artemisinin retention rate to over 95%. This invention has a clear material basis, controllable quality, and is suitable for preparing drugs or health products for the prevention and treatment of viral pneumonia.

The invention discloses a kit and method for detecting myxovirus drug-resistant protein A based on polypeptide and application, and belongs to the technical field of proteomics. The amino acid sequence of the polypeptide is as shown in SEQ ID No. 29. The polypeptide is obtained based on enzymolysis of an MxA standard substance and screening, a standard curve is established by utilizing the polypeptide and isotope labeled polypeptide, a biological sample is further subjected to enzymolysis to obtain a peptide fragment sample, and MxA in the biological sample can be quantified by detecting the content of the polypeptide in the peptide fragment sample. By utilizing the method disclosed by the invention, the MxA in the biological sample can be rapidly quantified, so that the viral pneumonia and the bacterial pneumonia are diagnosed and distinguished, and the accuracy rate is high.

This invention belongs to the field of traditional Chinese medicine pharmaceutical technology, specifically relating to the use of loliolide, a sesquiterpene compound, in the treatment of viral pneumonia. The invention isolates and extracts loliolide from *Lysimachia christinae*. Whole-animal experiments have confirmed that this compound has a good therapeutic effect on H1N1 influenza A virus-induced viral pneumonia in mice, significantly improving body weight, lung index, lung inflammation, viral titer, and pathological changes in virus-infected mice. Loliolide can be further used to prepare new drugs for the treatment of viral pneumonia.

The invention relates to the technical field of immunodiagnosis, in particular to application of TRPM2 in evaluation of viral pneumonia prognosis. The TRPM2 is used as a key immune marker, a novel detection system for viral pneumonia disease course monitoring and disease assessment is constructed, disease progression and treatment response can be accurately and dynamically reflected in the early stage, and the accuracy of viral pneumonia clinical risk assessment and intervention decision is remarkably improved.

The present invention refers to an in vitro method for identifying biomarkers or biomarker signatures for the differential diagnosis between viral and bacterial pneumonia in a patient, for the differential diagnosis between viral and bacterial pneumonia in a patient and / or for selecting a therapy for a patient suffering from pneumonia.

The application provides a traditional Chinese medicine effective part composition, a preparation method and application thereof. The traditional Chinese medicine effective part composition comprises the following weight parts of effective part medicines of traditional Chinese medicine compound preparation medicines: 125-2000 parts of polysaccharide parts, 0.625-2.5 parts of alkaloid parts, 6.25-100 parts of volatile oil parts and 6.25-100 parts of total glycoside parts. The traditional Chinese medicine compound preparation medicines comprise Poria cocos, Glycyrrhiza uralensis Fisch., Citrus aurantium, Platycodon grandiflorum, Bupleurum smithii, Gypsum fibrosum, Anemarrhena asphodeloides, Peucedanum decursivum, Notopterygium incisum, Cimicifuga foetida, Saposhnikovia divaricata, Schizonepeta, Chuanxiong, Pueraria lobata, Mentha haplocalyx, Lonicera japonica, Forsythia suspensa, Agastache rugosa, Ephedra sinica and Atractylodes lancea. The application further discloses a preparation method of the traditional Chinese medicine effective part composition and application of the traditional Chinese medicine effective part composition in preparing medicines for treating influenza and viral pneumonia. The influenza is influenza A, and the viral pneumonia is pneumonia induced by influenza A virus. A medicine for treating influenza and viral pneumonia comprises the traditional Chinese medicine effective part composition.